vs
Guardian Pharmacy Services, Inc.（GRDN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Guardian Pharmacy Services, Inc.的1.9倍（$772.1M vs $397.6M），Revvity净利率更高（12.7% vs 5.3%，领先7.5%）
CVS药房是美国零售企业，为CVS健康旗下子公司，总部位于罗德岛州文索基特，前身为Consumer Value Stores，1963年在马萨诸塞州洛厄尔成立，是美国知名的零售药房服务提供商，在药品零售、健康服务领域拥有广泛的业务布局。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
GRDN vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.9倍
$397.6M
净利率更高
RVTY
高出7.5%
5.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $397.6M | $772.1M |
| 净利润 | $20.9M | $98.4M |
| 毛利率 | 21.5% | — |
| 营业利润率 | 7.7% | 14.5% |
| 净利率 | 5.3% | 12.7% |
| 营收同比 | — | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GRDNRVTY
| Q4 25 | $397.6M | $772.1M | ||
| Q3 25 | $377.4M | $698.9M | ||
| Q2 25 | $344.3M | $720.3M | ||
| Q1 25 | $329.3M | $664.8M | ||
| Q4 24 | — | $729.4M | ||
| Q3 24 | $314.4M | $684.0M | ||
| Q2 24 | — | $691.7M | ||
| Q1 24 | — | $649.9M |
净利润GRDNRVTY
| Q4 25 | $20.9M | $98.4M | ||
| Q3 25 | $9.8M | $46.7M | ||
| Q2 25 | $9.0M | $53.9M | ||
| Q1 25 | $9.4M | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | $-122.0M | $94.4M | ||
| Q2 24 | — | $55.4M | ||
| Q1 24 | — | $26.0M |
毛利率GRDNRVTY
| Q4 25 | 21.5% | — | ||
| Q3 25 | 19.8% | 53.6% | ||
| Q2 25 | 19.8% | 54.5% | ||
| Q1 25 | 19.5% | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 19.4% | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率GRDNRVTY
| Q4 25 | 7.7% | 14.5% | ||
| Q3 25 | 4.3% | 11.7% | ||
| Q2 25 | 3.7% | 12.6% | ||
| Q1 25 | 3.9% | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | -33.3% | 14.3% | ||
| Q2 24 | — | 12.4% | ||
| Q1 24 | — | 6.8% |
净利率GRDNRVTY
| Q4 25 | 5.3% | 12.7% | ||
| Q3 25 | 2.6% | 6.7% | ||
| Q2 25 | 2.6% | 7.5% | ||
| Q1 25 | 2.9% | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | -38.8% | 13.8% | ||
| Q2 24 | — | 8.0% | ||
| Q1 24 | — | 4.0% |
每股收益（稀释后）GRDNRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $65.6M | $919.9M |
| 总债务越低越好 | $0 | — |
| 股东权益账面价值 | $217.9M | $7.3B |
| 总资产 | $412.7M | $12.2B |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资GRDNRVTY
| Q4 25 | $65.6M | $919.9M | ||
| Q3 25 | $36.5M | $931.4M | ||
| Q2 25 | $18.8M | $991.8M | ||
| Q1 25 | $14.0M | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $37.2M | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务GRDNRVTY
| Q4 25 | $0 | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $34.3M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益GRDNRVTY
| Q4 25 | $217.9M | $7.3B | ||
| Q3 25 | $195.5M | $7.4B | ||
| Q2 25 | $179.7M | $7.6B | ||
| Q1 25 | $163.2M | $7.6B | ||
| Q4 24 | — | $7.7B | ||
| Q3 24 | $133.9M | $7.9B | ||
| Q2 24 | — | $7.9B | ||
| Q1 24 | — | $7.8B |
总资产GRDNRVTY
| Q4 25 | $412.7M | $12.2B | ||
| Q3 25 | $390.0M | $12.1B | ||
| Q2 25 | $356.3M | $12.4B | ||
| Q1 25 | $334.0M | $12.4B | ||
| Q4 24 | — | $12.4B | ||
| Q3 24 | $348.0M | $12.8B | ||
| Q2 24 | — | $13.4B | ||
| Q1 24 | — | $13.4B |
负债/权益比GRDNRVTY
| Q4 25 | 0.00× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.26× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $34.6M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 1.65× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流GRDNRVTY
| Q4 25 | $34.6M | $182.0M | ||
| Q3 25 | $28.2M | $138.5M | ||
| Q2 25 | $19.9M | $134.3M | ||
| Q1 25 | $17.6M | $128.2M | ||
| Q4 24 | — | $174.2M | ||
| Q3 24 | — | $147.9M | ||
| Q2 24 | — | $158.6M | ||
| Q1 24 | — | $147.6M |
自由现金流GRDNRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | $24.2M | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率GRDNRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | 6.4% | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度GRDNRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | 1.1% | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率GRDNRVTY
| Q4 25 | 1.65× | 1.85× | ||
| Q3 25 | 2.87× | 2.97× | ||
| Q2 25 | 2.21× | 2.49× | ||
| Q1 25 | 1.86× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GRDN
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
